World Wires · story 5391 · unverified · 1 source(s)

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial

NewAmsterdam Pharma dosed the first participant in the Phase 2b SPINOZA trial evaluating obicetrapib for preclinical Alzheimer's disease.

Open in the desk

Coverage

• NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial GlobeNewswire: public companies · tier D · clear net · 2026-09-29 12:00 UTC

What this site indexes